Literature DB >> 30865225

Molecular screening to select therapy for advanced cancer?

I F Tannock1, J A Hickman2.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 30865225     DOI： 10.1093/annonc/mdz088

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  7 in total

1.  Talking the Talk About Tumor Genomic Testing.

Authors:  Richard L Schilsky
Journal:  J Natl Cancer Inst       Date:  2020-05-01       Impact factor: 13.506

2.  Lessons learned: the first consecutive 1000 patients of the CCCMunichLMU Molecular Tumor Board.

Authors:  Kathrin Heinrich; Lisa Miller-Phillips; Frank Ziemann; Korbinian Hasselmann; Katharina Rühlmann; Madeleine Flach; Dorottya Biro; Michael von Bergwelt-Baildon; Julian Holch; Tobias Herold; Louisa von Baumgarten; Philipp A Greif; Irmela Jeremias; Rachel Wuerstlein; Jozefina Casuscelli; Christine Spitzweg; Max Seidensticker; Bernhard Renz; Stefanie Corradini; Philipp Baumeister; Elisabetta Goni; Amanda Tufman; Andreas Jung; Jörg Kumbrink; Thomas Kirchner; Frederick Klauschen; Klaus H Metzeler; Volker Heinemann; C Benedikt Westphalen
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-07       Impact factor: 4.322

3.  Functional diagnostics using fresh uncultured lung tumor cells to guide personalized treatments.

Authors:  Sarang S Talwelkar; Mikko I Mäyränpää; Lars Søraas; Swapnil Potdar; Jie Bao; Annabrita Hemmes; Nora Linnavirta; Jon Lømo; Jari Räsänen; Aija Knuuttila; Krister Wennerberg; Emmy W Verschuren
Journal:  Cell Rep Med       Date:  2021-08-17

Review 4.  Molecular profiling for precision cancer therapies.

Authors:  Eoghan R Malone; Marc Oliva; Peter J B Sabatini; Tracy L Stockley; Lillian L Siu
Journal:  Genome Med       Date:  2020-01-14       Impact factor: 11.117

5.  Profiling of circulating tumor DNA and tumor tissue for treatment selection in patients with advanced and refractory carcinoma: a prospective, two-stage phase II Individualized Cancer Treatment trial.

Authors:  Jakob M Riedl; Samantha O Hasenleithner; Gudrun Pregartner; Lukas Scheipner; Florian Posch; Karin Groller; Karl Kashofer; Stephan W Jahn; Thomas Bauernhofer; Martin Pichler; Herbert Stöger; Andrea Berghold; Gerald Hoefler; Michael R Speicher; Ellen Heitzer; Armin Gerger
Journal:  Ther Adv Med Oncol       Date:  2021-02-27       Impact factor: 8.168

6.  Actionable Molecular Alterations Are Revealed in Majority of Advanced Non-Small Cell Lung Cancer Patients by Genomic Tumor Profiling at Progression after First Line Treatment.

Authors:  Malene Støchkel Frank; Uffe Bodtger; Julie Gehl; Lise Barlebo Ahlborn
Journal:  Cancers (Basel)       Date:  2021-12-28       Impact factor: 6.639

Review 7.  Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?

Authors:  Laura Bonanno; Alessandro Dal Maso; Alberto Pavan; Elisabetta Zulato; Lorenzo Calvetti; Giulia Pasello; Valentina Guarneri; PierFranco Conte; Stefano Indraccolo
Journal:  Br J Cancer       Date:  2022-03-09       Impact factor: 9.075
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.